Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Human immunodeficiency virus, genital herpes, and other sexually transmitted infections are a critical national and global health priority requiring the rapid development of safe and effective control methods. Topical microbicides, self-administered agents designed for vaginal use, that block transmission at the mucosal surface may provide a realistic method of intervention that could be distributed worldwide. An optimal microbicide should protect against infection but must also be safe, without adversely affecting the mucosal environment, including mediators of host defense. Thus, a critical component in microbicides development is to identify optimal assays that could serve as surrogate markers to predict safety of microbicides prior to embarking on large-scale clinical trials. This will require a greater understanding of the mediators of mucosal immunity in the female genital tract.

Original languageEnglish (US)
Pages (from-to)356-363
Number of pages8
JournalAmerican Journal of Reproductive Immunology
Volume56
Issue number5-6
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Mucosal Immunity
Sexually Transmitted Diseases
Anti-Infective Agents
Herpes Genitalis
Health Priorities
Local Anti-Infective Agents
Biomarkers
Clinical Trials
HIV
Safety
Infection

Keywords

  • Genital herpes
  • Human immunodeficiency virus
  • Microbicides
  • Mucosal immunity

ASJC Scopus subject areas

  • Immunology
  • Obstetrics and Gynecology

Cite this

@article{d91a5429156b48ca96d09d93849b3628,
title = "Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract",
abstract = "Human immunodeficiency virus, genital herpes, and other sexually transmitted infections are a critical national and global health priority requiring the rapid development of safe and effective control methods. Topical microbicides, self-administered agents designed for vaginal use, that block transmission at the mucosal surface may provide a realistic method of intervention that could be distributed worldwide. An optimal microbicide should protect against infection but must also be safe, without adversely affecting the mucosal environment, including mediators of host defense. Thus, a critical component in microbicides development is to identify optimal assays that could serve as surrogate markers to predict safety of microbicides prior to embarking on large-scale clinical trials. This will require a greater understanding of the mediators of mucosal immunity in the female genital tract.",
keywords = "Genital herpes, Human immunodeficiency virus, Microbicides, Mucosal immunity",
author = "Keller, {Marla J.} and Betsy Herold",
year = "2006",
month = "11",
doi = "10.1111/j.1600-0897.2006.00436.x",
language = "English (US)",
volume = "56",
pages = "356--363",
journal = "American Journal of Reproductive Immunology and Microbiology",
issn = "1046-7408",
publisher = "Wiley-Blackwell",
number = "5-6",

}

TY - JOUR

T1 - Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract

AU - Keller, Marla J.

AU - Herold, Betsy

PY - 2006/11

Y1 - 2006/11

N2 - Human immunodeficiency virus, genital herpes, and other sexually transmitted infections are a critical national and global health priority requiring the rapid development of safe and effective control methods. Topical microbicides, self-administered agents designed for vaginal use, that block transmission at the mucosal surface may provide a realistic method of intervention that could be distributed worldwide. An optimal microbicide should protect against infection but must also be safe, without adversely affecting the mucosal environment, including mediators of host defense. Thus, a critical component in microbicides development is to identify optimal assays that could serve as surrogate markers to predict safety of microbicides prior to embarking on large-scale clinical trials. This will require a greater understanding of the mediators of mucosal immunity in the female genital tract.

AB - Human immunodeficiency virus, genital herpes, and other sexually transmitted infections are a critical national and global health priority requiring the rapid development of safe and effective control methods. Topical microbicides, self-administered agents designed for vaginal use, that block transmission at the mucosal surface may provide a realistic method of intervention that could be distributed worldwide. An optimal microbicide should protect against infection but must also be safe, without adversely affecting the mucosal environment, including mediators of host defense. Thus, a critical component in microbicides development is to identify optimal assays that could serve as surrogate markers to predict safety of microbicides prior to embarking on large-scale clinical trials. This will require a greater understanding of the mediators of mucosal immunity in the female genital tract.

KW - Genital herpes

KW - Human immunodeficiency virus

KW - Microbicides

KW - Mucosal immunity

UR - http://www.scopus.com/inward/record.url?scp=33750541721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750541721&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0897.2006.00436.x

DO - 10.1111/j.1600-0897.2006.00436.x

M3 - Article

C2 - 17076680

AN - SCOPUS:33750541721

VL - 56

SP - 356

EP - 363

JO - American Journal of Reproductive Immunology and Microbiology

JF - American Journal of Reproductive Immunology and Microbiology

SN - 1046-7408

IS - 5-6

ER -